{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:28:30Z","timestamp":1792787310214,"version":"4.5.0"},"reference-count":18,"publisher":"BMJ","issue":"9","funder":[{"DOI":"10.13039\/501100000272","name":"National Institute for Health and Care Research","doi-asserted-by":"publisher","award":["NIHR203308"],"award-info":[{"award-number":["NIHR203308"]}],"id":[{"id":"10.13039\/501100000272","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000272","name":"National Institute for Health and Care Research","doi-asserted-by":"publisher","award":["NIHR304303"],"award-info":[{"award-number":["NIHR304303"]}],"id":[{"id":"10.13039\/501100000272","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Manchester University NHS Foundation Trust","award":["Not applicable"],"award-info":[{"award-number":["Not applicable"]}],"id":[{"id":"https:\/\/ror.org\/00he80998","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Med Genet"],"accepted":{"date-parts":[[2026,4,21]]},"published-print":{"date-parts":[[2026,9]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      Since 2020, the UK National Institute for Health and Care Excellence (NICE) recommends screening for Lynch syndrome in all people newly diagnosed with endometrial cancer. Screening involves tumour testing for loss of the mismatch repair (MMR) proteins using immunohistochemistry (IHC),\n                      <jats:italic>MLH1<\/jats:italic>\n                      methylation testing and germline sequencing for Lynch syndrome according to a diagnostic algorithm. Here we review adherence to NICE guidance at a gynaecological cancer centre in North-West England.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a prospective audit of Lynch syndrome screening for consecutive patients newly diagnosed with endometrial cancer discussed at the gynaecological oncology multidisciplinary (MDT) meeting. We recorded adherence with the NICE recommended diagnostic algorithm, testing turnaround times and the impact of gynaecology-led genetic testing (mainstreaming) on diagnostic intervals.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Between November 2021 and November 2023, 421 new endometrial cancer patients were discussed at MDT. Overall, 96.9% (408\/421) underwent IHC and 26.0% (106\/408) were MMR deficient, mostly due to\n                      <jats:italic>MLH1<\/jats:italic>\n                      hypermethylation (17.4%, 71\/408). In total, 7.1% (29\/408) had MMR deficiency not due to\n                      <jats:italic>MLH1<\/jats:italic>\n                      hypermethylation (25\/408 had\n                      <jats:italic>MSH2\/MSH6\/PMS2<\/jats:italic>\n                      loss and 4\/408 were non-hypermethylated) that required germline testing for Lynch syndrome, and 3.2% (13\/408) had Lynch syndrome. Only 19\/27 (70.4%) with positive tumour triage underwent Lynch syndrome testing (four declined and four died before testing). The median time from tumour MMR IHC results to germline test result was 121 days (IQR 103, 133) with gynaecology-led testing compared with 278 days (IQR 183, 476) with testing organised by clinical genetics.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The prevalence of Lynch syndrome in our unselected endometrial cancer population was 3.2% but not everyone at risk was tested. Some declined germline Lynch syndrome testing due to a lack of at-risk family members and delay getting their genetic appointment. A significant minority died before they could be offered or receive Lynch syndrome testing. We recommend gynaecology-led germline testing and referral to clinical genetics only patients with confirmed Lynch syndrome. This approach would ease the burden of an already overstretched genetics service while promptly identifying Lynch syndrome in high-risk patients. This in turn enables timely colorectal cancer surveillance and cascade testing of at-risk family members.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/jmg-2026-111578","type":"journal-article","created":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T17:20:28Z","timestamp":1779988828000},"page":"554-560","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":0,"title":["Identification of Lynch syndrome among people newly diagnosed with endometrial cancer: a prospective audit"],"prefix":"10.1136","volume":"63","author":[{"given":"Jean-Ellen","family":"Johnson","sequence":"first","affiliation":[{"name":"Department of Gynaecology, Manchester University NHS Foundation Trust, Manchester, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Milliken","sequence":"additional","affiliation":[{"name":"Department of Gynaecology, Manchester University NHS Foundation Trust, Manchester, UK"},{"name":"Department of Obstetrics and Gynaecology, Royal Infirmary of Edinburgh, Edinburgh, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Bolton","sequence":"additional","affiliation":[{"name":"Histopathology, Manchester University NHS Foundation Trust, Manchester, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D Gareth","family":"Evans","sequence":"additional","affiliation":[{"name":"Manchester Centre for Genomic Medicine, Manchester University NHS Foundation Trust, Manchester, UK"},{"name":"Division of Evolution, Infection and Genomic Sciences, The University of Manchester, Manchester, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fiona","family":"Lalloo","sequence":"additional","affiliation":[{"name":"Manchester Centre for Genomic Medicine, Manchester University NHS Foundation Trust, Manchester, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0284-8630","authenticated-orcid":false,"given":"Emma J","family":"Davidson","sequence":"additional","affiliation":[{"name":"Department of Gynaecology, Manchester University NHS Foundation Trust, Manchester, UK"},{"name":"Division of Cancer Sciences, The University of Manchester, Manchester, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2026,5,28]]},"reference":[{"key":"2026102307200989000_63.9.554.1","doi-asserted-by":"publisher","DOI":"10.1111\/tog.12706"},{"key":"2026102307200989000_63.9.554.2","doi-asserted-by":"publisher","DOI":"10.1038\/s41436-019-0596-9"},{"key":"2026102307200989000_63.9.554.3","doi-asserted-by":"publisher","DOI":"10.1038\/s41436-019-0489-y"},{"key":"2026102307200989000_63.9.554.4","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1003263","article-title":"The proportion of endometrial tumours associated with Lynch syndrome (PETALS): a prospective cross-sectional study","volume":"17","author":"Ryan","year":"2020","journal-title":"PLoS Med"},{"key":"2026102307200989000_63.9.554.5","unstructured":"National Institute for Health and Care Excellence . Testing strategies for Lynch syndrome in people with endometrial cancer (DG42). 2020."},{"key":"2026102307200989000_63.9.554.6","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)00323-3"},{"key":"2026102307200989000_63.9.554.7","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.06.7173"},{"key":"2026102307200989000_63.9.554.8","doi-asserted-by":"crossref","first-page":"183","DOI":"10.2147\/TACG.S48625","article-title":"Clinical problems of colorectal cancer and endometrial cancer cases with unknown cause of tumor mismatch repair deficiency (suspected Lynch syndrome)","volume":"7","author":"Win","year":"2014","journal-title":"TACG"},{"key":"2026102307200989000_63.9.554.9","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2023.e17495","article-title":"Clinicopathological characteristics of endometrial carcinomas according to DNA mismatch repair protein status","volume":"9","author":"de Freitas","year":"2023","journal-title":"Heliyon"},{"key":"2026102307200989000_63.9.554.10","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1097\/COC.0000000000000871","article-title":"Effect of mismatch repair status on outcome of early-stage grade 1 to 2 endometrial cancer treated with vaginal brachytherapy","volume":"45","author":"Russo","year":"2022","journal-title":"Am J Clin Oncol"},{"key":"2026102307200989000_63.9.554.11","unstructured":"Idos G , Valle L . Lynch syndrome. In: GeneReviews at GeneTests: medical genetic information resource. 2021."},{"key":"2026102307200989000_63.9.554.12","doi-asserted-by":"publisher","DOI":"10.1002\/bjs.11902"},{"key":"2026102307200989000_63.9.554.13","doi-asserted-by":"publisher","DOI":"10.1038\/s41431-020-0692-y"},{"key":"2026102307200989000_63.9.554.14","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1111\/j.1399-0004.2007.00779.x","article-title":"Genetic counselling and consent for tumour testing in HNPCC","volume":"71","author":"Gaff","year":"2007","journal-title":"Clin Genet"},{"key":"2026102307200989000_63.9.554.15","doi-asserted-by":"crossref","DOI":"10.3390\/jcm9061842","article-title":"Feasibility of gynaecologist led Lynch syndrome testing in women with endometrial cancer","volume":"9","author":"Ryan","year":"2020","journal-title":"J Clin Med"},{"key":"2026102307200989000_63.9.554.16","doi-asserted-by":"crossref","DOI":"10.1136\/bmjoq-2024-003014","article-title":"Implementing recommendations for routine mismatch repair (MMR) immunohistochemistry (IHC) testing of endometrial cancer and subsequent patient management","volume":"14","author":"Shawky","year":"2025","journal-title":"BMJ Open Qual"},{"key":"2026102307200989000_63.9.554.17","doi-asserted-by":"publisher","DOI":"10.1111\/1471-0528.16432"},{"key":"2026102307200989000_63.9.554.18","doi-asserted-by":"crossref","DOI":"10.1136\/bmjonc-2024-000688","article-title":"Mismatch in testing: a retrospective analysis of mismatch repair testing in endometrial cancer and Lynch syndrome diagnosis in multiple specialist centres in the UK and Ireland (March 2022\u2013March 2023)","volume":"4","author":"Ryan","year":"2025","journal-title":"bmjonc"}],"container-title":["Journal of Medical Genetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jmg-2026-111578","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T14:20:33Z","timestamp":1792765233000},"score":1,"resource":{"primary":{"URL":"https:\/\/jmg.bmj.com\/lookup\/doi\/10.1136\/jmg-2026-111578"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,28]]},"references-count":18,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2026,8,26]]},"published-print":{"date-parts":[[2026,9]]}},"alternative-id":["10.1136\/jmg-2026-111578"],"URL":"https:\/\/doi.org\/10.1136\/jmg-2026-111578","relation":{},"ISSN":["0022-2593","1468-6244"],"issn-type":[{"value":"0022-2593","type":"print"},{"value":"1468-6244","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,28]]}}}